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Abstract: The optimal treatment of early (T1 and T2) rectal adenocarcinomas remains controversial. Local
excision and radical resection with total mesorectal excision are the two surgical techniques for excising
early rectal cancer. Each has their respective benefits, with local excision allowing for decreased operative
morbidity and mortality while radical resection provides an oncologically complete treatment through
lymphadenectomy. Local excision can be accomplished via transanal endoscopic microsurgery or transanal
excision. There is no significant difference in the recurrence rates (21% vs. 33%) or overall survival (80%
vs. 66%) between the two local excision modalities; however, transanal endoscopic microsurgery does allow
for a higher rate of R0 resection. Current selection criteria for local excision include well to moderately
differentiated tumors without high-risk features such as lymphovascular invasion, perineural invasion, or
mucinous components. In addition, tumors should ideally be <3 cm in size, excised with a clear margin,
occupy less than 1/3 of the circumference of the bowel and be mobile/nonfixed. Despite these stringent
inclusion criteria, local excision continues to be plagued with a high recurrence rate in both T1 and T2
tumors due to a significant rate of occult locoregional metastases (20% to 33%). For both tumor groups,
the recurrence rate in the local excision group is more than double compared to radical resection. However,
the overall survival is not significantly different between those with and without metastases. With intense
postoperative surveillance, these recurrences can be identified early while they are confined to the pelvis
allowing for salvage surgical options. Recently, neoadjuvant therapy followed by local excision has shown
favorable short and long-term oncological outcomes to radical resection in the treatment of T2 rectal cancer.
Ultimately, the management of early rectal cancer must be individualized to each patient’s expectations of
quality and quantity of life. With informed consent, patients may be willing to accept a higher failure rate
and an increased post-operative surveillance regimen to preserve a perceived increased quality of life.
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Introduction
Concurrent with the widespread use of population based
screening programs, there are more than 42,000 newly
diagnosed cases of rectal cancer each year (1). Radical
surgical resection of both the primary tumor and the
draining lymph node basin (by either low anterior or
abdominoperineal resection) remains the corner stone of
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curative therapy in rectal cancer of all stages. However,
the staging accuracy of endorectal ultrasound (ERUS) and
pelvic magnetic resonance imaging (MRI) has led some
to question the necessity of a major surgical resection for
early T-stage cancers when the entire tumor burden could
(theoretically) be resected complete by transanal excision.
The optimal treatment of early rectal adenocarcinoma
remains debatable, although most surgeons recommend
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Table 1 Appropriate tumor selection for local excision
Characteristics

Favorable

Unfavorable

1

Well differentiated

Poorly differentiated

2

Moderately differentiated

3

No lymphovascular invasion

Lymphovascular invasion

4

No perineural invasion

Perineural invasion

5

No mucinous components

Evidence of mucin production

6

Invasion to level sm1 and sm2

Invasion to level sm3

<3 cm in size

>3 cm in size

<1/3 the circumference of the rectal wall

>1/3 the circumference of the rectal wall

<10 cm from the anal verge
7

Mobile lesion

>10 cm from the anal verge
Fixed lesion

sm, submucosa; cm, centimeter.

radical resection for T2 lesions.
The surgical approach to rectal cancer has evolved
continually over the last 100 years. The trend towards
less invasive surgical procedures is clear: from the initial
attempts at trans-sacral resection, to the popularization of
universal abdominoperineal resection (the Miles procedure),
followed by acceptance of low anterior resection (greatly
facilitated by surgical stapling technology). Transanal, local
excision of early cancers is the logical extension of this
trend. At present, radical resection with total mesorectal
excision (TME) is the surgical standard of care for rectal
cancer. This approach completely removes the primary
tumor and draining lymph node basin, allowing accurate
and complete pathological staging. Radical resection with
TME is also fully curative in patients with node-negative
and early T-stage cancers. However, radical resection carries
a 2-3% perioperative mortality rate and 20-30% overall
complication rate (2). Additionally, long-term complications
such as sexual impotence, decreased fecundity in women,
alterations in bowel function (e.g., the anterior resection
syndrome), and the potential for a permanent ostomy all
adversely affect quality of life (2-5).
In contrast, local excision avoids the common
complications associated with a major operation allowing
for decreased anesthesia, minimal fluid shifts and blood
loss in combination with a shorter hospital stay and
quicker recovery. But the decreased invasiveness comes
at the expense of an oncologically incomplete surgery.
Advocates for local excision assert that failure due to occult
mesorectal lymph node metastases is potentially treatable
with salvage total mesorectal excision. Although current
imaging modalities have improved, some patients will not
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be accurately staged. Only after presenting with a local
failure will they receive appropriate adjuvant therapy. For
this reason, local excision mandates a strict adherence to
an intense post-operative surveillance schedule extending
beyond 5 years to detect any recurrence.
Appropriate patient and tumor selection remain a major
obstacle to transanal excision of rectal cancer, although
advances in understanding tumor biology may improve
this process. There are no widely accepted guidelines for
utilizing local excision. In general, it is reserved for tumors
isolated to the submucosa (T1) that are well to moderately
differentiated with low-risk histopathological features.
Lymphovascular invasion, perineural invasion, and mucinous
components are considered high-risk characteristics, and
local excision should be avoided due to an increased rate
of lymph node metastasis. In addition, tumors should
ideally be <3 cm in size with a clear margin, occupy less
than 1/3 of the circumference of the bowel and be mobile/
nonfixed (6). Despite these stringent inclusion criteria, local
excision continues to be plagued with a high recurrence
rate (Table 1). The goal for the treatment of early (T1 and
T2) rectal cancer is to optimize oncologic control while
minimizing the long-term impact of treatment on quality of
life (7). This paper will review the data for both T1 and T2
adenocarcinomas, as well some of the promising surgical and
combined modalities for treating these early cancers.
Transanal excision for T1 adenocarcinoma
Cancer biology differs substantially throughout the lower
gastrointestinal tract, with a predisposition for early lymph
node spread in the rectum compared to the proximal
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Table 2 Outcomes after local excision vs. radical surgery for T1 adenocarcinoma of the rectum
Series

Surgery performed

N

High grade (%)

LR (%)

DR (%)

OS (%)

DFS (%)

Median F/U (mo)

Local excision
Garcia-Aguilar et al., 1999

TAE

55

0

16.0

4.0

82

77

52

Paty et al., 2002

TAE

74

15.0

17.0

–

74

–

120

Gopaul et al., 2004

TAE

32

–

13.0

–

–

–

37

Bentrem et al., 2005

TAE

151

9.0

15.0

12.0

89

93

60

Endreseth et al., 2005

TAE

35

1.0

12.0

0

70

64

60

Madbouly et al., 2005

TAE

0

23.0

12.0

75

70

55

You et al., 2007

LE-ANS

601

5.3

8.2

3.6

77

93

60

Nash et al., 2009

TAE

137

52.0

19.0

19.0

69

83

59

Doornebosch et al., 2010

TEM

88

6.0

21.0

8.0

–

–

36

168

10.0

3.0

3.0

93

97

60

52

Radical resection
Bentrem et al., 2005

RR-NOS

Endreseth et al., 2005

LAR/APR

256

15.0

6.0

7.0

80

77

60

You et al., 2007

RR-NOS

493

7.5

4.3

2.6

82

97

60

Nash et al., 2009

LAR/APR

145

–

–

–

85

94

77

TAE, transanal excision; TEM, transanal endoscopic microsurgery; LE-ANS, local excision, approach not specified; LAR, low
anterior resection; APR, abdominoperineal resection; RR-NOS, radical resection, not otherwise specified; LR, local recurrence;
DR, distant recurrence; OS, overall survival; DFS, disease free survival; F/U, follow-up; mo, months.

colon (4). Although limited to the bowel submucosa, T1
rectal cancer has a 13-25% rate of occult lymph node
spread compared to only 3-8% in the colon (4,8). While it’s
not uncommon to retrieve 1 or 2 lymph nodes along with
a full-thickness transanal resection, the nodal basin is not
sufficiently staged by local excision alone. Despite lingering
concerns about the adequacy of a transanal excision, a
paradoxical increase in the use of local excision for T1
tumors occurred in the United States between 1989-2003 (9).
Subsequently, several authors have cautioned against local
excision, citing excessively high local recurrence rates and
worse oncological outcomes (see below), possibly due to
lack of rigorous patient and tumor selection.
Most neoplasms less than 10 cm from the anal verge
can be resected transanally. Local excision results in a fullthickness specimen including some mesorectal fat. At least
1 cm circumferential mucosal margins should be obtained.
The specimen is usually pinned to corkboard or sponge
by the surgeon to avoid confusion over orientation and
specimen contraction from soaking in Formalin. The defect
in the bowel wall is subsequently closed, typically in a
transverse manner to prevent restriction of the rectal lumen.
Patients perform a full mechanical bowel preparation prior
to the surgery, but recovery postoperatively is rapid, with
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early resumption of regular diet and activity and minimal
discomfort.
ERUS and/or pelvic MRI are mandatory for the preoperative
staging of rectal cancers. ERUS is more sensitive in
distinguishing early bowel invasion of the primary, while
MRI is superior at evaluating mesorectal lymph nodes
and the circumferential resection margin. The utility of
combining ERUS and MRI to direct surgical therapy has
also been explored by various investigators (10). Recently
though, several studies have reported a significantly lower
sensitivity rate (48-54%) of ERUS for detecting early
T1 cancer as compared to higher staged lesions (11,12).
The success of transanal excision relies on the accuracy of
preoperative clinical staging as it fails to address possible
occult lymph node metastasis. Presumably the higher
regional recurrence rate following local excision is at least
in part explained by a failure of preoperative imaging
modalities to detect micro-metastatic disease within
mesorectal lymph nodes.
The literature on local recurrence rates after transanal
excision for T1 rectal cancer is comprised mostly of
retrospective studies containing a heterogeneous population
of high and low risk lesions (Table 2). Despite the differences
between the series, the type of surgery (transanal excision
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vs. radical resection) remains a constant predictor of local
recurrence, with radical resection always maintaining a
lower local recurrence rate. The gap between the treatment
modalities does narrow though when stratifying tumors
by both clinical and pathologic criteria. Blumberg and
colleagues demonstrated that excluding high-risk factors
(lymphovascular invasion, mucin production, poor
differentiation) and applying strict clinical factors (distance
from anal verge and size) could decrease the lymph node
metastases rate from 16% to 7% (2.3 fold) (5). Kikuchi et al.
showed that not all T1 tumors behave in the same manner,
and their invasiveness stems from the level of submucosal
infiltration. For tumors only slightly invading the
submucosa (sm1) there were no nodal metastases observed,
as opposed to tumors invading the deepest one-third of the
submucosa (sm3) that had a 25% rate of metastases (13).
Sm3 depth of invasion has been confirmed by other authors
as a contraindication for local excision (8). Greenberg et al.
provided long-term follow-up on the prospective CALGB
8984 study of local excision of T1 rectal cancer (14). The
authors found a local recurrence rate of only 8% at 7.1 years
median follow-up using stringent selection criteria. Others
have confirmed that oncological outcomes in prospective
series seem improved relative to the larger retrospective
reports, reinforcing the importance of strict attention to
patient and tumor selection (2).
Although there is an increased local recurrence rate
between the surgical modalities, this has failed to translate
into a survival benefit. After 5 years, there is an overall
survival rate of 70-89% vs. 77-97% and disease free survival
rate of 64-93% vs. 80-93% in the transanal excision and
radical resection groups, respectively (2,4). Conversely,
the similar survival rates may reflect an inadequate followup time. During 10 years of follow-up by Nash et al., the
authors found a similar overall survival in the first 4 years
after diagnosis but an increased rate of cancer-related death
between 4-8 years (peak period of cancer recurrence) in the
transanal excision group. Only after 9 years did death from
other causes dominate in the transanal excision group (12).
Patients undergoing local excision must be committed to a
long-term follow-up schedule to detect recurrences.
If high-risk features are identified in the original
pathologic specimen, an immediate radical resection should
be performed. This does not compromise outcomes and
has a 94% disease free survival rate at 5 years (15). In this
manner, the transanal excision may be viewed as a “large
biopsy”, the results of which may direct further immediate
surgery. However, the aggressive use of salvage surgery
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after identifying a local recurrence can still allow for an
R0 resection to be accomplished in a majority of cases
(77%) (4). With routine post-operative surveillance, the
detection rate is up to 88% with proctoscopy and ERUS
alone, although most centers also utilize either computed
tomography (CT) or MRI (16). Salvage surgery, though,
comes with the cost of increased morbidity compared to
an initial radical resection and may require multivisceral
resection and an ostomy in up to 43% (4). After salvage
surgery, the 5-year overall survival is significantly decreased
to 43-56.2% compared to those without a recurrence
(3,4). The relatively poor outcomes following salvage
surgery emphasize the importance of the appropriate initial
treatment of early rectal cancer.
Transanal excision for T2 adenocarcinoma
Similar to T1 tumors, there was almost a fifty percent
increase across the US between 1989-2003 in the use of local
excision to treat T2 rectal cancer (12% to 21%) (7). While
local excision is now generally an acceptable treatment of
T1 tumors, there is a growing concern about extending its
application to T2. Transanal excision of T2 tumors carries a
nearly double local recurrence rate compared to T1 lesions,
ranging from 13-30% for the more advanced primary
lesions (Table 3). The higher local recurrence rate is likely
due to the increased occult nodal metastasis rate of 2838% (17). Conversely, radical resection has only a slightly
increased rate of local recurrence at 7.2% compared to that
for T1 tumors (9). This finding emphasizes both the staging
and therapeutic benefits of total mesorectal excision.
The increased invasiveness and locoregional metastatic
potential of T2 tumors is also reflected in the decreased
overall survival, and the difference is increased for patients
undergoing local excision as compared to radical resection.
In the nationwide cohort study by You et al., there was
a significant difference in overall survival (68% vs. 77%,
P=0.01) between local excision and radical resection (9).
This was strongly impacted, though, by nononcologic
factors related to the patient [age (>75) and multiple
comorbidities (>2)] rather than the type of surgery. The
disease-free survival did not differ (90% vs. 92%, P=0.95)
at 5 years, likely due to early death by other non-cancer
related causes (9). Given the advanced age and poor health
of this study population, they may not have been candidates
for a radical resection. Nevertheless, the 90% disease free
survival in the radical resection group demonstrates the
effectiveness of the procedure in providing a cure.
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Table 3 Outcomes after local excision vs. radical surgery for T2 adenocarcinoma of the rectum
Series

Surgery performed

N

High grade (%)

LR (%)

DR (%)

OS (%)

DFS (%) Median F/U (mo)

Local excision
Garcia-Aguilar et al., 1999

TAE

27

0

30.0

7.0

63

55

58

Paty et al., 2002

TAE

51

–

28.0

–

75

–

120

Gopaul et al., 2004

TAE

25

–

24.0

–

–

–

37

You et al., 2007

LE-ANS

164

13.4

13.0

5.0

68

90

60

RR-NOS

866

7.9

7.2

7.7

77

92

60

Radical resection
You et al., 2007

TAE, transanal excision; TEM, transanal endoscopic microsurgery; LE-ANS, local excision, approach not specified; RR-NOS,
radical resection, not otherwise specified; LR, local recurrence; DR, distant recurrence; OS, overall survival; DFS, disease free
survival; F/U, follow-up; mo, months.

Table 4 Outcomes after neoadjuvant chemoradiation therapy for T2 adenocarcinoma of the low rectum
Series

Surgery performed

N

Chemo vs. radiation

LR (%)

DR (%)

OS (%)

DFS (%) Median F/U (mo)

Local excision
Nair et al., 2008

TAE

10

Both

10

10

81

–

60

Lezoche et al., 2012

TEM

50

Both

8

4

72

89

115

Perez et al., 2013

TEM

18

Both

14

19

85

68

15

Lap LAR

50

Both

6

4

80

94

115

Radical resection
Lezoche et al., 2012

TAE, transanal excision; TEM, transanal endoscopic microsurgery; Lap LAR, laparoscopic low anterior resection; LR, local
recurrence; DR, distant recurrence; OS, overall survival; DFS, disease free survival; F/U, follow-up; mo, months.

At present, it seems imprudent to locally excise T2 rectal
cancers in fit patients (11). Local excision offers a moderate
chance of cure and is reasonable for patients in whom major
surgery is contraindicated due to medical comorbidities.
Transanal excision after neoadjuvant
chemoradiation
Neoadjuvant chemoradiation has consistently demonstrated
the ability to reduce local recurrence rates and downstage
primary tumors in select patients with rectal cancers
(18,19). This has sparked interest in its application in early
rectal cancer (20). Most of the neoadjuvant and adjuvant
scheduled in the literature used a similar of radiation dose (50.454 Gy), and all chemotherapy regimens are 5-fluoruracil (5FU) based. As shown in Table 4, tumor downstaging and
downsizing has been demonstrated in 51-64% and 26-100%
of T2 rectal cancers, respectively (20,21). It is important to
note that complete clinical response only translates to a 3060% pathologically complete response for which there is
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minimal disease recurrence (20-22). Lezoche et al. reported
that overall recurrences occurred primarily in the low
response and non-responder groups, at rates of 12% after
local excision and 10% after radical resection (21). A more
aggressive surgical approach is indicated for these patients,
as an incomplete response likewise may exist in the regional
lymph nodes (22). Using a neoadjuvant regimen consisting
of 4,500 cGy in 25 fractions of radiation over three fields
with a boost of 540 cGy to the tumor in conjunction with
a continuous infusion of 300 mg m–2 day–1 of 5-FU on days
of radiation over a 5-week course, Nair et al. noted that the
overall survival was not significantly different between the
local excision group and radical resection group (72% vs.
80%, P=0.61) (22). In the transanal excision of T2 rectal
cancer, neoadjuvant therapy has shown favorable shortterm and similar long-term oncological outcomes to radical
resection.
The improved oncologic benefits of combined
chemoradiation therapy do not come without a price.
Chemo-radiation increases the rate of post-operative
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complications; however, most of these are minor
complications (91%) that can be managed without
additional surgery (20). The most common side effects were
gastrointestinal, dermatologic, and hematologic.
The use of neoadjuvant therapy for T2 rectal cancer
should not be over utilized, though, as radical surgery alone
provides an adequate treatment for T2 N0 disease. It’s
role may be to downsize and downstage borderline T2-T3
tumors. Local excision may then be utilized to determine
the pathological response to the chemoradiation. If there is
only a partial response and tumor still remains, immediate
radical resection should be performed. It is the authors’
current practice to determine surgical treatment prior to
initiating neoadjuvant therapy.
Transanal endoscopic microsurgery for T1 and
T2 adenocarcinoma
Transanal endoscopic microsurgery (TEM) for local
excision of rectal adenomas was originally described by
Dr. Buess of Germany in 1983. Although the technique
and instruments have undergone refinement over the
past 30 years, the surgical principles have remained the
same. The patient is positioned on the table (lithotomy,
prone jackknife, lateral decubitus) such that the tumor is
in the posterior position. A specialized set of instruments
including a 40 mm rectoscope and laparoscopic style tools
are required, although newer minimally invasive equipment
can be adapted for transanal use (e.g., transanal minimally
invasive surgery). After appropriate insufflation of the
rectum, the tumor is visualized and a 1 cm circumferential
margin marked with electrocautery. A full thickness excision
is then performed, the specimen oriented on the back table
and the resulting defect closed transversely with absorbable
sutures.
TEM is similar to transanal excision in that patients
can expect a short (1-2 day) hospital stay, decreased
complications and quicker recovery. The complication
rate after TEM is <5% and includes bleeding, rectovaginal
fistula, transient incontinence to gas and stool, and transient
urinary retention (23). There are several key differences,
though, between the two operations. TEM often requires
a general anesthetic to perform the procedure, which may
be contraindicated in patients with severe cardiopulmonary
disease, opposed to spinal or local anesthesia for traditional
transanal excision. The superior visualization and
instrumentation afforded by TEM relative to traditional
transanal excision often permits en bloc specimen
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removal, thus avoiding piecemeal resection. This allows
for an increased rate of R0 resection and a more accurate
histological evaluation of the circumferential and deep
margin.
TEM is the gold-standard operation for the resection of
rectal adenomas, but its use as a curative option for rectal
carcinoma is debatable. Despite having a significantly
decreased rate of R1 resection between TEM and
traditional transanal excision (2% vs. 16%) (24), achieving
an R0 resection did not prevent local recurrence (16).
Even when stratifying to low-risk T1 tumors, there is still
a 17% local recurrence rate after TEM (16). There was no
significant difference in the 5-year recurrence rate between
T1 and T2 tumors removed by either local excision
technique (21% vs. 33%, P=0.07) (24). Due to the high rate
of local recurrence in low-risk patients with even an R0
resection, improving criteria for tumor resection by TEM is
of major importance.
TEM suffers from the same shortcomings as traditional
transanal excision in being unable to adequately stage the
pelvis. Using the same post-operative surveillance schedule
as transanal excision, most recurrences can be detected early
enough to allow for salvage surgery. Short term followup after salvage surgery shows a cancer-related survival of
79% at 1 year and 58% at 3 years, which is comparable
to transanal excision (16). Between the two local excision
modalities, the 5-year disease free survival (85% vs. 70%,
P=0.146) and overall survival (80% vs. 66%, P=0.119) were
similar across both T1 and T2 lesions (24).
In summary, TEM provides better visualization of
the tumor allowing for a more proficient operation to be
performed. However, this has not translated to improved
local recurrence or overall survival compared to traditional
transanal excision. While some authors advocate for TEM
as the treatment of choice for local excision, patient and
tumor-specific features remain paramount regardless of the
surgical approach. Further studies are needed examining
the relative effectiveness of TEM compared to traditional
transanal excision.
Surveillance following local excision
Following local excision, a long-term surveillance schedule
is mandatory to identify recurrences that are potentially
resectable and metachronous lesions. Although centers
vary slightly in their follow-up regimen, each consists
of at least a semiannual history and physical exam,
carcinoembryonic antigen (CEA), and proctoscopy in
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conjunction with annual imaging (CT or MRI) (4,6,11).
There has been an increased trend in the combined use
of CT/MRI with ERUS postoperatively to increase the
sensitivity in detecting locoregional recurrences. It is the
authors’ current practice to perform a history and physical
examination every 3-6 months for the first 2 years and then
annually after. A baseline CEA is obtained prior to surgery
and then followed at every appointment. To detect mucosal
recurrences, a digital rectal exam and proctoscopy or flexible
sigmoidoscopy are performed every 3-6 months for 2 years
and then yearly after. This is alternated with ERUS every
6 months to evaluate for lymph node metastases. Finally, a
CT or MRI is obtained annually to detect local or distant
recurrences. Most surveillance schedules only extend out
to five years, but given the propensity for late recurrences,
long-term follow-up after local excision should be pursued.
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